Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report

Clin Genitourin Cancer. 2012 Sep;10(3):207-9. doi: 10.1016/j.clgc.2012.01.011. Epub 2012 Mar 23.

Authors

Christina J Perry¹, Santhanam Sundar

Affiliation

¹ Department of Clinical Oncology, Nottingham City Campus, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. cperry@doctors.org.uk

PMID: 22445962
DOI: 10.1016/j.clgc.2012.01.011

No abstract available

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Neoplasms / blood
Bone Neoplasms / diagnosis*
Bone Neoplasms / drug therapy
Bone Neoplasms / secondary
Docetaxel
Drug Resistance, Neoplasm
Fatal Outcome
Humans
Male
Neoplasm Recurrence, Local*
Prednisolone / administration & dosage
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / blood
Prostatic Neoplasms / diagnosis*
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / pathology
Taxoids / administration & dosage
Treatment Outcome

Substances

Taxoids
Docetaxel
cabazitaxel
Prednisolone
Prostate-Specific Antigen